Accepted Manuscript

Non-vitamin K antagonist oral anticoagulants (NOACs) in adult congenital heart disease

François-Pierre Mongeon, MD, SM, Laurent Macle, MD, Luc M. Beauchesne, MD, Berto J. Bouma, MD, PhD, Markus Schwerzmann, MD, Barbara J.M. Mulder, MD, PhD, Paul Khairy, MD, PhD

PII: S0828-282X(19)30443-X

DOI: <https://doi.org/10.1016/j.cjca.2019.06.022>

Reference: CJCA 3316

To appear in: *Canadian Journal of Cardiology*

Received Date: 26 February 2019

Revised Date: 18 June 2019

Accepted Date: 18 June 2019

Please cite this article as: Mongeon F-P, Macle L, Beauchesne LM, Bouma BJ, Schwerzmann M, Mulder BJM, Khairy P, Non-vitamin K antagonist oral anticoagulants (NOACs) in adult congenital heart disease, *Canadian Journal of Cardiology* (2019), doi: <https://doi.org/10.1016/j.cjca.2019.06.022>.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Non-vitamin K antagonist oral anticoagulants (NOACs) in adult congenital heart disease

François-Pierre Mongeon MD, SM^{1,2}; Laurent Macle MD³; Luc M. Beauchesne MD³;
Berto J. Bouma MD, PhD⁵; Markus Schwerzmann MD⁶; Barbara J.M. Mulder MD, PhD⁷;
Paul Khairy MD, PhD^{1,3}

¹Adult congenital heart center, Department of medicine, Montreal Heart Institute, Université de Montréal, Montreal QC, Canada

²Division of non-invasive cardiology, Department of medicine, Montreal Heart Institute, Université de Montréal, Montreal QC, Canada

³Division of electrophysiology, Department of medicine, Montreal Heart Institute, Université de Montréal, Montreal QC, Canada

⁴Division of cardiology, University of Ottawa Heart Institute, Ottawa ON, Canada

⁵Department of cardiology, Academic Medical Center, Amsterdam, The Netherlands

⁶Center for Congenital Heart Disease, University hospital Inselspital, University of Bern, Switzerland

⁷Department of cardiology, Amsterdam University Medical Center, Amsterdam, The Netherlands

Short title: Mongeon & Khairy — NOACs in ACHD

Word count: 9117 (all inclusive)

Address for correspondence and reprint requests:

François-Pierre Mongeon, MD, SM

Division of non-invasive cardiology & Adult Congenital Heart Center, Montreal Heart Institute
5000 Bélanger Street, Montréal, QC, Canada H1T 1C8

Phone: 514-593-2159; Fax: 514-593-2158

e-mail: francois-pierre.mongeon@icm-mhi.org

ABBREVIATIONS

- CHA₂DS₂-VASc: Congestive heart failure, Hypertension, Age (65-74 years 1 point, ≥ 75 years 2 points), Diabetes mellitus, Stroke, transient ischemic attack or thromboembolism (2 points), VAScular disease (history of myocardial infarction, peripheral arterial disease or aortic atherosclerosis), female Sex Category
- CHADS₂: Congestive heart failure, Hypertension, Age ≥ 75 years, Diabetes mellitus, Stroke, transient ischemic attack or thromboembolism (2 points)
- CHD: Congenital Heart Disease
- HAS-BLED: Hypertension (systolic blood pressure > 160 mmHg), Abnormal liver or renal function, Stroke, Bleeding tendency or predisposition, Labile INR in patients taking a VKA, Elderly (age > 65 years), Drugs (antiplatelet agents or alcohol use)
- INR: International normalized ratio
- NOAC(s): Non-vitamin K antagonist oral anticoagulants
- RR: Relative risk
- VKA: Vitamin K Antagonist(s)

ABSTRACT

Non-vitamin K antagonist oral anticoagulants (NOACs) have several advantages over vitamin K antagonists (VKA) that render them an attractive option for adults with congenital heart disease (CHD). Efficacy and safety data specific to the adult CHD population are emerging. Herein, we synthesize the growing literature regarding NOACs in adults with CHD and attempt to identify subgroups for which it appears reasonable to extrapolate data from populations without CHD. Small observational studies suggest that NOACs are safe and effective in selected adults with CHD. NOACs are contraindicated in patients with a mechanical valve, in those with mitral or tricuspid valve stenosis with enlarged and diseased atria, with or without a mitral or tricuspid bioprosthesis, and after recent cardiac surgery (<3 months). There is currently insufficient evidence to recommend NOACs in patients with a Fontan circulation or cyanotic CHD. Growing literature supports the use of NOACs in patients without CHD who have various forms of valvular heart disease. Therefore, when an indication for oral anticoagulation is established, it appears reasonable to consider a NOAC instead of a VKA in adults with CHD lesions analogous to isolated mitral regurgitation, tricuspid regurgitation, or aortic regurgitation or stenosis. The NOAC agent selected and the prescribed dose should be tailored according to bleeding risk, body weight, renal function, and co-medications, especially antiepileptic drugs. The decision to initiate a NOAC should be shared between the patient and care provider. Large-scale research studies are required to further assess safety and efficacy in selected patient subgroups.

KEY WORDS: Adult congenital heart disease; anticoagulation; non-vitamin K antagonist oral anticoagulant; vitamin K antagonist

SUMMARY

It appears reasonable to use a non-vitamin K antagonist oral anticoagulant (NOAC) instead of a vitamin K antagonist in adults with an indication for oral anticoagulation and congenital heart disease (CHD) analogous to structural heart diseases included in NOACs trials. NOACs are contraindicated in patients with mechanical valves, atrioventricular valve stenosis with enlarged and diseased atria with or without a bioprosthesis, or recent cardiac surgery. Insufficient evidence supports the use of NOACs in patients with a Fontan circulation or cyanotic CHD.

INTRODUCTION

The growing population of adults with congenital heart disease (CHD) faces a 10 to 100-fold higher risk of thromboembolic complications than age-matched controls¹. Thromboembolic and bleeding risks are not uniform across the various forms of CHD such that the indication for anticoagulation and the choice of antithrombotic agent could be influenced by the underlying cardiac pathology^{2,3}. Patients with cyanotic CHD are at highest risk for cerebrovascular accidents⁴. While vitamin K antagonists (VKA) emerged as the *de facto* oral anticoagulant for lack of rival agents, non-VKA anticoagulants (NOACs) entered the scene with the completion of the first large clinical trial in 2009⁵. They have since usurped VKAs as the agents of choice in patients with non-valvular atrial fibrillation⁶ and venous thromboembolism⁷, with the promise of more predictable pharmacokinetics, fewer drug-drug and food-drug interactions, greater ease of use, and a more attractive risk-to-benefit profile (Table 1).

It is, therefore, tempting to extrapolate data from large clinical trials to the adult CHD population in the hopes of improving outcomes. However, caution is warranted in generalizing the results of clinical trials to a non-target population. NOACs can be less safe and effective than VKAs in certain conditions⁸ and precautions regarding selection of agents and dose-adjustments are required on the basis of clinical circumstances. There is no substitute for clinical research in assessing the value of NOACs in the adult CHD population. Ongoing studies, such as the multinational NOACs for atrial tachyarrhythmias in congenital heart disease (NOTE) registry (www.clinicaltrials.gov NCT02928133), have begun providing reassuring short-term safety data and will no doubt shed light on longer-term outcomes in the future⁹⁻¹³. In the interim, a review of present knowledge could help inform current practice regarding subgroups of adults with CHD for whom it may be reasonable to prescribe a NOAC when anticoagulation is indicated. Such an

approach has similarly been used to refine indications and contraindications to NOACs in patients with valvular heart disease¹⁴.

INDICATIONS FOR ANTICOAGULATION IN ADULTS WITH CHD

Adults with CHD harbor various risk factors for thromboembolism that include CHD complexity, atrial arrhythmias, prior thromboembolic events (including paradoxical emboli), right-to-left shunts (e.g., cyanotic CHD), pulmonary hypertension, Fontan circulation, intrinsic coagulation abnormalities, valvular prosthesis, and pregnancy, along with factors that are captured by standard risk scores such as CHA₂DS₂-VASc¹⁵. There are, therefore, numerous reasons as to why an adult with CHD may require systemic anticoagulation.

Atrial arrhythmias

Contemporary prevalence estimates for atrial arrhythmias in adults with CHD range from 10 to 15%^{16, 17}, with projections suggesting that over 50% of those with complex CHD will develop atrial arrhythmias by 65 years of age¹⁷. Among adults with CHD, those with atrial arrhythmias have a two-fold higher risk of stroke¹⁷. Adults with CHD may have important risk factors for stroke that are not captured by standard risk scores such that decisions regarding anticoagulation should be made in concert with an adult CHD specialist. For example, practice guidelines recognize that adults with moderate or complex CHD (see Supplementary Table S1 for a classification of CHD complexity)^{2, 15} and intra-atrial reentrant tachycardia (atrial flutter) or atrial fibrillation could benefit from anticoagulation despite a CHA₂DS₂-VASc score of 0².

The type and prevalence of arrhythmia depends, in part, on the heart defect, type of repair, surgical incisions, residual hemodynamic lesions and age¹⁵. Defects associated with the highest prevalence of atrial arrhythmias include Ebstein anomaly, transposition of the great arteries with

atrial baffles, univentricular hearts, atrial septal defects, and tetralogy of Fallot¹. Atrial fibrillation is particularly common in patients with residual left-sided lesions or single ventricle physiology¹⁸. In contemporary cohorts of patients with CHD and atrial arrhythmias, the risk of thromboembolic complications ranges from 11 to 14 per 1,000 patient-years when antithrombotic therapy is at the physician's discretion^{19,20}. In a multicenter cohort of 482 patients with CHD and atrial arrhythmias, complexity of CHD was the only factor independently associated with thromboembolic events²⁰. As shown in Table 2, in comparison to study populations included in NOAC trials for non-valvular atrial fibrillation, the on-treatment residual annual rate of stroke or systemic embolism is similar in adults with CHD despite their younger age and fewer traditional risk factors.

Fontan circulation

Thromboembolic complications can have devastating consequences in patients with a Fontan circulation and have been associated with mortality in some²¹ but not all studies^{22,23}. The risk of thromboembolism is non-linear and rises sharply at two different points in time: within 2-3 years and 15 years after Fontan surgery²¹. Many associated factors have been identified including atrial arrhythmias, a fenestration (for systemic thromboembolic events), prior thrombosis, an atriopulmonary connection with atrial flow stasis, a blind pulmonary artery stump or hypoplastic cardiac chambers with flow stasis, bilateral cavopulmonary anastomoses, protein-losing enteropathy, prolonged pleural effusions, ventricular dysfunction, intrinsic coagulation abnormalities and thrombogenic material²⁴⁻²⁶. Anticoagulation has consistently been recommended for Fontan patients with a residual atrial shunt, atrial thrombus, atrial arrhythmias, or a prior thromboembolic event¹. Many patients with an atriopulmonary Fontan circulation harbor thrombotic risk factors that may justify long-term anticoagulation (class IIb, level of

evidence C according to the scientific statement on prevention and treatment of thrombosis in pediatric and congenital heart disease from the American Heart Association)²⁴.

Eisenmenger syndrome

Pulmonary artery dilatation, stasis, endothelial injury, older age and biventricular dysfunction favour the formation of mural thrombi in patients with Eisenmenger syndrome²⁷⁻³¹, which, in turn, can cause artery-to-artery embolization. By 35 years of age, 13% of patients have had a clinically recognized pulmonary embolism³². A VKA can treat pulmonary emboli in the presence of thrombus in the central pulmonary arteries, but routine anticoagulation to prevent thrombus formation is not indicated³³. Risks and benefits of anticoagulation must be carefully weighed, considering that anticoagulation does not improve survival^{34,35}. The prevalence of stroke in patients with Eisenmenger syndrome is 8-14%^{32,36} and increases to 47% if routine cerebral MRI is performed³⁷. Female sex, low oxygen saturation, advanced age, biventricular dysfunction, low functional capacity, and pulmonary artery aneurysm are associated with an increased risk of thrombus^{28,30,33,37,38}. Atrial fibrillation, pulmonary hypertension, microcytosis and iron deficiency, as a consequence of inappropriate phlebotomies, also favour the occurrence of stroke³⁶. On the other hand, Eisenmenger syndrome carries a substantial bleeding risk due to reduced levels of coagulation factors (II, V, VII, IX, X) and von Willebrand factor multimers, along with increased fibrinolytic activity³³.

Right-to-left shunt

In general, patients with a probable embolic stroke and patent foramen ovale who do not undergo closure should receive antithrombotic therapy. A recent expert panel issued a weak recommendation in favour of oral anticoagulants over antiplatelet therapy³⁹. Although a NOAC is

not considered contraindicated in this setting, the current experience is largely with VKAs³⁹. In patients with intracardiac shunts, shunt closure is generally recommended prior to intra-cardiac lead implantation, barring a contraindication^{40, 41}. If the shunt is not closed, oral anticoagulation should be considered in light of the increased thromboembolic risk.

MECHANISM OF ACTION OF NOACs

NOACs are small molecules that bind to the active site of a single protease in the coagulation cascade⁴². In contrast, VKAs reduce the production of active proteases by interfering with the gamma-carboxylation of vitamin K dependant coagulation (II, VII, IX, X) and antithrombotic (protein C, S and Z) factors⁴². NOAC binding is reversible such that their effect can be overcome by increasing the thrombogenic substrate or by a strong procoagulant stimulus⁴². For example, the brain contains very high levels of tissue factor, the main initiator of coagulation. Exposure of blood to brain tissue may overcome the effect of a NOAC, suggesting a mechanism for the reduced occurrence of intracranial haemorrhage⁴². The dose relationship between NOAC level and intensity of coagulation is more linear than with VKA because the inhibition of a single protease is more predictable than inhibition of multiple steps of the coagulation cascade⁴². This may partially account for the more favourable safety profile of NOACs⁴².

Dabigatran

Dabigatran (PradaxaTM) is a small hirudin analog that prevents the conversion of fibrinogen to fibrin by inhibiting thrombin (factor IIa)⁴³. The effect of dabigatran may be reversed by idarucizumab (PraxbindTM), a monoclonal antibody⁴⁴.

The RE-ALIGN trial, which was prematurely terminated because of an excess of thromboembolic and bleeding events in patients with mechanical valves on high-dose dabigatran

compared to VKA, raises concerns about the role of NOACs in the setting of prosthetic material⁸. Mechanical valves appear to induce sufficient thrombin generation to overcome the effect of dabigatran at clinically relevant concentrations⁴⁵. The semicircular leaflets and Dacron or Teflon sewing ring promote thrombin generation by activating factor XII and the intrinsic coagulation pathway more than metallic leaflets⁴⁵. To achieve a therapeutic effect similar to an INR between 2 and 3.5, considerably higher concentrations of dabigatran (>200 ng/mL) than tested in REALIGN (>50 ng/mL)⁸ are required, with prohibitive bleeding risks⁴⁵. Importantly, bioprosthetic heart valves also have Dacron sewing rings such that an initial 3-month course of VKA can be helpful in reducing the risk of thrombosis while the ring undergoes endothelialization⁴⁵. These concepts are relevant to CHD patients with similar prosthetic material. The use of NOACs in patients with mechanical valves, particularly factor Xa inhibitors, may eventually be reconsidered⁴⁶.

Rivaroxaban, apixaban and edoxaban

Rivaroxaban (XareltoTM), apixaban (EliquisTM), and edoxaban (LixianaTM) prevent the conversion of prothrombin to thrombin (factor IIa) by inhibiting coagulation factor Xa⁴³. Their effects may be reversed by andexanet alpha, a modified recombinant factor Xa molecule that binds NOACs⁴⁷.

EVIDENCE SPECIFIC TO CHD

Evidence for the use of NOACs in adults with CHD is emerging in the form of observational studies. In a series of 75 adults with CHD on NOACs by Pujol et al, 31 had a pre-tricuspid shunt, 16 complex CHD, 5 cyanosis, and 3 a Fontan circulation¹². Most were anticoagulated for atrial arrhythmias (76%) or history of stroke/transient ischemic attack (20%) and were predominantly

treated with rivaroxaban (73%)¹². The population had a low bleeding risk, with a HAS-BLED score ≤ 1 in 72% of patients¹². No thrombotic or major bleeding event occurred during a mean follow-up of 12 months¹². Similarly, Yang et al reported an early international experience on 99 adults with CHD (56% moderate CHD, 29% complex CHD, 33% with a history of heart failure, 11% with Fontan palliation) all of whom had atrial arrhythmias¹³. Apixaban was the most commonly prescribed agent (62%) and the median HAS-BLED score was 0. After 30 days of therapy, 8 minor events (5 minor bleeds, 3 side effects) occurred in the 54 patients that had transitioned from a VKA to a NOAC. These findings were considered reassuring, particularly in patients with moderate or complex CHD¹³. Cheng et al reported 13 patients with CHD treated with a NOAC for a median 570 days⁹. More gastrointestinal side effects were observed with dabigatran⁹.

Georgekutty et al reviewed their experience with NOACs in 21 patients with a Fontan circulation anticoagulated because of arrhythmias (12), thrombosis (8) or persistent right-to-left shunt (2)¹⁰. A NOAC was prescribed on the basis of patient or provider preference, labile INR on a VKA, initiation of therapy in another center, or non-compliance with follow-up. Ten minor bleeding events occurred with no major bleed. During a total of 316 patient-months of therapy, one patient with protein-losing enteropathy and right-to-left shunting through a fenestration had deep vein thrombosis while on dabigatran. Another patient had progression of Fontan circuit thrombosis while on apixaban. Pinto et al also reported the progression of thrombus in a patient with a lateral tunnel Fontan and atrial flutter on apixaban¹¹. The NOTE registry included 74 patients with a Fontan circulation. During a median follow-up of 1.2 years, 3 (4.1%) thromboembolic events and 3 (4.1%) major bleeds occurred. Although adverse event rates were not statistically significantly higher than with VKAs during a brief follow-up period (personal

communication from Barbara J.M. Mulder), the limited experience precludes definitive endorsement of NOAC use in Fontan patients until further evidence becomes available.

EVIDENCE ABOUT NOACs RELEVANT TO CHD

Non-valvular atrial fibrillation

The results of four large clinical trials (RE-LY, ROCKET-AF, ARISTOTLE, ENGAGE AF-TIMI 48) in patients with atrial fibrillation were pooled in a meta-analysis that included 42,411 patients randomized to a NOAC versus 29,972 patients on warfarin⁶. NOACs significantly reduced stroke and systemic embolism [relative risk (RR) 0.81, 95% confidence interval (CI) 0.73-0.91, $p<0.0001$], haemorrhagic stroke (RR 0.49, 95% CI 0.38-0.64, $p<0.0001$), all-cause mortality (RR 0.90, 95% CI 0.85-0.95, $p=0.0003$) and intracranial haemorrhage (RR 0.48, 95% CI 0.39-0.59, $p<0.0001$)⁶. Considering all NOACs, there was a highly suggestive trend towards a reduction in major bleeding (RR 0.86, 95% CI 0.73-1.00, $p=0.06$). The trend was consistent for all agents except rivaroxaban (RR 1.03, 95% CI 0.90-1.18, $p=0.72$)^{6, 48}. Lower-dose NOACs (dabigatran 110 mg twice daily or edoxaban 30 mg / 15 mg daily) were associated with a similar reduction in stroke and systemic embolism compared to warfarin (RR 1.03, 95% CI 0.84-1.27, $p=0.74$), fewer major bleeds (RR 0.65, 95% CI 0.43-1.00, $p=0.05$) and intracranial haemorrhages (RR 0.31, 95% CI 0.24-0.41, $p<0.0001$), but more ischemic strokes (RR 1.28, 95% CI 1.02-1.60, $p=0.045$)⁶. The increased risk of ischemic stroke appears to be driven by results with the 30 mg / 15 mg edoxaban daily regimen^{49, 50}. The effects of NOACs were consistent in subgroup analyses according to age, sex, history of diabetes, prior stroke or transient ischemic attack, creatinine clearance, CHADS₂ score, and prior use of a VKA⁶.

Subgroups of patients with atrial fibrillation and valvular heart disease

Patients with atrial fibrillation and valvular heart disease have more adverse events

None of the NOAC trials has specifically targeted patients with valvular heart disease. All trials excluded patients with mechanical valves or severe mitral stenosis, and only ENGAGE AF-TIMI 48 (edoxaban) allowed enrolling subjects with bioprosthetic valves. In addition, ROCKET-AF (rivaroxaban) excluded patients with “hemodynamically relevant valve disease”⁴⁸ and patients with moderate or severe mitral stenosis did not qualify for enrolment in ARISTOTLE (apixaban)⁵¹ or ENGAGE AF-TIMI 48 (edoxaban)⁴⁹. Nevertheless, 13-26% of patients included in the major NOAC trials had some form of valve disease^{52, 53}, allowing for substudies and meta-analyses summarized in Table 3. Patients with valvular heart disease were older, more often female, had more comorbidities, more permanent or persistent atrial fibrillation, and had higher CHADS₂ and HAS-BLED scores⁵³⁻⁵⁶. Overall, higher adverse event rates were observed in patients with valve disease¹⁴. In the RE-LY trial (dabigatran), the presence of exclusive right-sided valve disease (tricuspid or pulmonary regurgitation) was associated with excess major bleeding in comparison to patients without valvular heart disease regardless of treatment assignment⁵³.

Stroke, systemic embolism, and bleeds in patients with atrial fibrillation and valve disease

NOACs appear to be as effective or superior to VKAs for the prevention of stroke or systemic embolism in patients with valvular heart disease, barring the types of valve disease excluded from the trials (Table 3). A lower incidence of major bleeding with a NOAC compared to a VKA was consistent across trials, with the exception of excess bleeding with rivaroxaban in patients with valve disease in ROCKET-AF⁵⁷. The patients with valvular heart disease in ROCKET-AF were older and had more comorbidities⁵⁷. Likewise, a consistent advantage of NOACs over VKAs was

observed in reducing the incidence of intracranial haemorrhage in patients with valve disease, with the exception of rivaroxaban.

Heterogeneity in the definitions of non-valvular and valvular atrial fibrillation

Heterogeneity in the definitions of valvular atrial fibrillation with variable exclusion criteria in the anticoagulation trials prompted a new Evaluated Heart valves Rheumatic or Artificial (EHRA) classification system¹⁴. According to the expert consensus statement, EHRA type 1 patients have atrial fibrillation in the setting of a mechanical valve or rheumatic or moderate to severe mitral stenosis and should receive a VKA as an anticoagulant¹⁴. EHRA type 2 patients have atrial fibrillation and other forms of valve disease such that a NOAC or VKA is considered acceptable, while taking the CHA₂DS₂-VASc score into consideration¹⁴. To date, no alarming signal regarding excess strokes or major bleeding events with apixaban or edoxaban has been detected by meta-analyses and substudies in patients with atrial fibrillation and bioprosthetic valves or prior valve surgery^{52, 54, 58}. However, a concern remains regarding NOAC use in patients with mitral bioprosthetic valves and prior rheumatic mitral valve disease with large and severely diseased atria such that a VKA may remain the better option in this scenario⁵⁹.

Implications for adults with CHD

Valve disease is common in adults with CHD. In the absence of CHD-specific evidence, it may be reasonable to prescribe a NOAC instead of a VKA to patients with atrial arrhythmias and categories of valve disease that are similar to those with reassuring efficacy and safety data from large NOAC trials. Examples include patients with bicuspid aortic valves and aortic stenosis or regurgitation, repaired tetralogy of Fallot with pulmonary regurgitation, Ebstein anomaly with tricuspid regurgitation, and congenital valve disease with a bioprosthetic valve that is not in the

systemic atrioventricular valve position, with normal or nearly normal atrial size. In contrast, NOACs should be avoided in adults with CHD who have a mechanical valve or a recent operation (<3 months) as suggested by Jaffer et al⁴⁵. It would also be prudent to avoid NOACs in patients with congenital mitral or tricuspid stenosis who have enlarged and severely diseased atria. There is no definitive data regarding NOACs in patients with a percutaneous valve prosthesis who require anticoagulation for another indication (such as atrial fibrillation). However, patients with transcatheter aortic valve replacement are classified as EHRA type 2, such that a NOAC is not considered contraindicated. The GALILEO trial tested the hypothesis that a rivaroxaban-based antithrombotic strategy (10 mg daily plus aspirin 75-100 mg daily for 90 days then rivaroxaban alone) would reduce the risk of thromboembolic complications after transcatheter aortic valve replacement with an acceptable risk of bleeding compared with the recommended antiplatelet therapy-based strategy (clopidogrel 75 mg daily plus aspirin 75-100 mg daily for 90 days followed by aspirin alone) in subjects without a need for chronic oral anticoagulation⁶⁰. This trial was recently terminated early due to excess harm (death and bleeding) in the rivaroxaban group.

Venous thromboembolism

NOACs are non-inferior to the combination of parenteral heparin and VKA for the acute treatment (3 months) of venous thromboembolism, and are associated with fewer bleeds⁷. There is also evidence for extended prevention of venous thromboembolism with dabigatran, apixaban or rivaroxaban after 3-12 months of initial therapy. Of note, recurrent venous thromboembolism is less frequent with either rivaroxaban 20 mg or 10 mg daily compared to aspirin, with no excess in major bleeds⁷. These data suggest that NOACs can offer antithrombotic benefits with a risk of bleeding comparable to aspirin. Even if the Fontan circulation could be considered a venous

circuit, data specific to patients with a Fontan circulation are required before extrapolating such results in light of the thrombotic concerns noted above.

Labile INR

On average, patients with atrial fibrillation on warfarin in clinical trials spend 65% of their time in the therapeutic range⁶. A greater reduction in bleeding events associated with NOACs is observed at centers with a time in the therapeutic range below 66%⁶, suggesting a larger benefit in patients with difficulties maintaining therapeutic INRs.

Heart failure

In patients with atrial fibrillation and a biventricular circulation with a systemic left ventricle, NOACs appear to be as safe and effective in patients with and without heart failure^{61, 62}. Moreover, NOACs have been associated with fewer intracranial haemorrhages in patients with heart failure⁶².

Underweight patients

Low body weight (<60 kg) is one of the criteria for a dose reduction with apixaban and edoxaban. Underweight patients taking a NOAC have a 4-fold higher risk of major bleeding compared to normal weight patients⁶³. Low body weight patients are underrepresented in large outcome trials but no difference in the efficacy of NOACs was detected in patients with a lower body weight⁵⁹.

Renal insufficiency

In a large series of adults with CHD, 50% had some degree of renal dysfunction⁶⁴. All NOACs are partially eliminated by the kidney (dabigatran 80%, edoxaban 50%, rivaroxaban 35%,

apixaban 27%) and should be dose-adjusted accordingly⁵⁹. Creatinine clearance should be estimated by the Cockcroft and Gault formula and monitored at a frequency corresponding to the creatinine clearance/10 in months⁵⁹. While all NOACs are effective and safe in subgroup analyses of pivotal trials, apixaban and edoxaban may have the best safety profile in patients with reduced renal function⁵⁹. The dose of rivaroxaban should be reduced to 15 mg daily if the creatinine clearance is 30-49 mL/min. Edoxaban and apixaban also have specific dose reduction criteria in the presence of renal insufficiency⁶⁵. Data from randomized controlled trials on NOAC use in patients with a creatinine clearance <30 mL/min are very limited. A large retrospective study of patients with atrial fibrillation on dialysis suggests that apixaban may be associated with fewer major bleeds and a similar risk of stroke or systemic embolism compared to a VKA⁶⁶. It may, therefore, be acceptable to use apixaban in some patients with end-stage renal disease and atrial fibrillation⁶⁷.

Liver disease

The prevalence of liver disease in adults with CHD is uncertain but is particularly high in patients with a Fontan circulation⁶⁸. Liver disease is both a thrombotic and haemorrhagic condition that interferes with drug metabolism. Patients with liver disease were excluded from pivotal NOAC trials⁵⁹. As such, NOACs should be used with caution in patients with Child-Turcotte-Pugh B cirrhosis and avoided in class C cirrhosis⁵⁹. Rivaroxaban should not be used in patients with liver dysfunction⁵⁹. NOACs do not appear to cause hepatotoxicity.

Women of reproductive age

NOACs are contraindicated during pregnancy and breastfeeding⁵⁹. About 32% of women of reproductive age taking a factor Xa inhibitor experience heavy menstrual bleeding⁶⁹.

Rivaroxaban is associated with prolonged menstrual bleeding, increased need for menorrhagia-related interventions, and more interruptions of anticoagulant therapy compared to warfarin⁷⁰. There is no data to suggest that these undesirable effects are limited to rivaroxaban. Women of childbearing age taking a NOAC should be counselled about the need for reliable contraception. If pregnancy is planned or occurs unexpectedly, a strategy should be in place to replace the NOAC with low molecular weight heparin under the supervision of a provider experienced in pregnancy and CHD.

BLEEDING RISK

Major bleeding is defined by the International Society on Thrombosis and Haemostasis as symptomatic bleeding in a critical area or organ, or bleeding leading to a drop in hemoglobin ≥ 2 g/dL or to transfusion of ≥ 2 red blood cell units⁵⁰. In the multicenter TACTIC study of CHD patients with atrial arrhythmias, the annualized rate of major bleeding on an oral anticoagulant (predominantly VKA) was 0.77%/year²⁰, which is substantially lower than the rates reported in clinical trials of NOACs or VKAs (Table 2). In general, the CHD population requiring anticoagulation is younger than patients enrolled in anticoagulation trials, with only 6.8% of patients in TACTIC having a HAS-BLED score ≥ 2 ²⁰. The HAS-BLED score was associated with major bleeds independent of CHD complexity²⁰. Thus, despite the presence of risk factors such as Eisenmenger syndrome, pulmonary hypertension, acquired von Willebrand disease, thrombocytopenia, and hepatic dysfunction¹⁵, on the whole the bleeding risk in CHD patients who require anticoagulation is generally low. There is no data to suggest that risk is higher with a NOAC. On the contrary, NOACs have consistently been associated with a lower risk of intracranial hemorrhage (odds ratio 0.49, 95% CI 0.36-0.45) compared to VKA or aspirin in a meta-analysis that included 57,491 patients⁷¹.

PATIENT PREFERENCE AND ADHERENCE TO THERAPY

The choice of oral anticoagulant must balance risks, benefits, and patient expectations in relation to underlying CHD and other comorbidities¹⁴. Decisions should, as much as possible, be shared between the patient and care provider and require the willingness and ability to take an oral anticoagulant, acceptance of the impact of anticoagulation on potential lifestyle changes, and an understanding of the consequences of thrombosis and risks of bleeding¹⁴.

It is crucial for patients to understand that a NOAC must be taken as prescribed to maintain protection against thromboembolism because therapeutic effects disappear within 12-24 hours. Non-adherence to a single dose of a VKA can be less consequential owing to the residual anticoagulant effects of prior doses⁷². Switching to a VKA can be considered in patients with poor adherence to a NOAC. Adherence and persistence rates vary between 49-99% depending on setting and definition but are likely better with once daily intake⁷². In comparison, the one-year discontinuation rate with VKAs is 26-35%⁷². The more active lifestyle and geographical mobility of the population of adults with CHD contribute to lesser adherence to medication intake¹⁵. Obviating the need for INR monitoring and follow-up at anticoagulation clinics may render NOAC therapy more appealing. This may also be the case for patients with INR self-monitoring considering the cost of the device and need for periodic calibration.

DRUG INTERACTIONS

Potential drug interactions with NOACs must be considered. Chang et al identified an increase in major bleeds in patients taking amiodarone, fluconazole, rifampin, and phenytoin in association with a NOAC⁷³. Amiodarone, diltiazem, and verapamil increase the serum concentration of dabigatran, edoxaban, and apixaban via P glycoprotein competition⁵⁹. In addition, diltiazem and

verapamil are CYP3A4 inhibitors, resulting in a further increase in NOAC levels⁵⁹. For adults with CHD who have epilepsy, additional relevant drug interactions with NOACs include carbamazepine, levetiracetam, phenobarbital, valproic acid, and topiramate⁵⁹. Consultation with a clinical pharmacist is suggested to minimize drug interactions.

SWITCHING FROM VKA TO NOAC

Denas et al used administrative data with propensity score matching to address the question of whether switching to a NOAC is advantageous for a patient with atrial fibrillation if a high proportion of time spent in the therapeutic range can be achieved with a VKA⁷⁴. While rates of stroke and major bleeding were similar between NOAC and VKA treated patients, the rate of intracranial haemorrhage was significantly lower with a NOAC⁷⁴. In a substudy of ROCKET-AF, rivaroxaban was associated with fewer bleeds in VKA-naïve patients and similar bleeding in VKA-experienced patients after 30 days of therapy⁷⁵. A SAME-TT₂R₂ score >2 (female sex, age <60 years, medical history, treatment with VKA-interacting drugs, tobacco use, non-Caucasian race) can help identify patients who are less likely to fare well on a VKA⁷⁶ but has not been validated in adults with CHD.

PRACTICAL TIPS

Key practical tips on using NOACs in adults with CHD, as adapted from recommendations from the European Heart Rhythm Association⁵⁹, are summarized in Table 4.

SUMMARY AND RECOMMENDATIONS FOR NOAC USE IN ADULTS WITH CHD

- Efficacy and safety data for NOACs in adults with CHD are limited to small observational studies that provide encouraging information.

- NOACs are contraindicated in adults with CHD and (1) a mechanical heart valve; (2) history of mitral or tricuspid valve stenosis with enlarged and diseased atria with or without a mitral or tricuspid bioprosthesis.
- VKAs are recommended over NOACs within 3 months after cardiac surgery.
- It would be premature to endorse the use of NOACs in patients with cyanotic CHD or Fontan physiology. Several cases of thrombus have been described in a small number of Fontan patients receiving NOACs. Larger series with longer follow-up are required.
- CHA₂DS₂-VASc and HAS-BLED scores have not been validated in patients with congenital heart disease although the risk factors for stroke or bleeding that they encompass may be relevant to adults with CHD and atrial arrhythmias. The indication for anticoagulation in a patient with CHD of moderate or great complexity should preferably be discussed with an ACHD cardiologist.
- A NOAC can be considered in adults with CHD and anticoagulation indications for atrial arrhythmias when the CHD lesions are analogous to isolated mitral regurgitation, tricuspid regurgitation, aortic regurgitation or stenosis. Suggested choices of antithrombotic medications for selected clinical situations are summarized in the Figure.
- NOAC use should not replace the recommended antiplatelet regimen after implantation of a transcatheter valve prosthesis.
- NOACs have consistently been associated with a decreased risk of intracranial haemorrhage compared to adjusted-dose VKAs.
- The dose of rivaroxaban should be adjusted to creatinine clearance. The dose of edoxaban should be adjusted to body weight and creatinine clearance. The dose of apixaban should be

adjusted to serum creatinine, age and body weight. Drug interactions, especially with antiepileptic drugs, should be taken into account.

- The decision to initiate a NOAC should be shared between the patient and care provider. The patient should be made aware of the paucity of data specific to adults with CHD.

CONCLUSION

Herein, we attempted to summarize current knowledge regarding NOAC use in adults with CHD as well as studies in the general population of relevance to congenital patients. The intention was to provide practical guidance regarding clinical situations in which it may or may not be reasonable to extrapolate data from large clinical trials to subgroups of the adult CHD population on the basis of similar anatomic and pathophysiological considerations. We acknowledge that there is no substitute for sound clinical research and that recommendations can change on the basis of new research findings. Robust studies are required to provide definitive evidence regarding the safety and efficacy of NOACs in the heterogeneous subgroups of adults with CHD. While CHD-specific registries will continue to offer important insights, randomized trials are required to overcome limitations inherent to observational studies, including confounding by indication.

REFERENCES

1. Khairy P. Thrombosis in congenital heart disease. *Expert Rev Cardiovasc Ther.* 2013;11:1579-1582.
2. Khairy P, Van Hare GF, Balaji S, et al. PACES/HRS Expert Consensus Statement on the Recognition and Management of Arrhythmias in Adult Congenital Heart Disease: developed in partnership between the Pediatric and Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS). Endorsed by the governing bodies of PACES, HRS, the American College of Cardiology (ACC), the American Heart Association (AHA), the European Heart Rhythm Association (EHRA), the Canadian Heart Rhythm Society (CHRS), and the International Society for Adult Congenital Heart Disease (ISACHD). *Heart Rhythm.* 2014;11:e102-165.
3. Stout KK, Daniels CJ, Aboulhosn JA, et al. 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Journal of the American College of Cardiology.* 2019;73:1494-1563.
4. Hoffmann A, Chockalingam P, Balint OH, et al. Cerebrovascular accidents in adult patients with congenital heart disease. *Heart (British Cardiac Society).* 2010;96:1223-1226.
5. Huynh K. Milestone 10: Era of the NOACs. *Nature reviews. Cardiology.* 2017.
6. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. *Lancet.* 2014;383:955-962.
7. Bromley A, Plitt A. A Review of the Role of Non-Vitamin K Oral Anticoagulants in the Acute and Long-Term Treatment of Venous Thromboembolism. *Cardiology and therapy.* 2018;7:1-13.
8. Eikelboom JW, Connolly SJ, Brueckmann M, et al. Dabigatran versus warfarin in patients with mechanical heart valves. *The New England journal of medicine.* 2013;369:1206-1214.
9. Cheng K, Harrogate S, Orchard E. The Use of Novel Oral Anticoagulants in Adult Congenital Heart Disease: A Single Center Experience. *The American journal of cardiology.* 2016;117:312-313.

10. Georgekutty J, Kazerouninia A, Wang Y, et al. Novel oral anticoagulant use in adult Fontan patients: A single center experience. *Congenit Heart Dis*. 2018;1-7.
11. Pinto C, Samuel BP, Ratnasamy C, Vettukattil JJ. Thrombosis in Fontan patient on apixaban. *International journal of cardiology*. 2015;182:66-67.
12. Pujol C, Niesert AC, Engelhardt A, et al. Usefulness of Direct Oral Anticoagulants in Adult Congenital Heart Disease. *The American journal of cardiology*. 2016;117:450-455.
13. Yang H, Bouma BJ, Mulder BJM. Is Initiating NOACs for Atrial Arrhythmias Safe in Adults with Congenital Heart Disease? *Cardiovascular drugs and therapy*. 2017;31:413-417.
14. Lip GYH, Collet JP, Caterina R, et al. Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLEACE). *Europace*. 2017;19:1757-1758.
15. Wan D, Tsui C, Kiess M, Grewal J, Krahn AD, Chakrabarti S. Anticoagulation for Thromboembolic Risk Reduction in Adults With Congenital Heart Disease. *Can J Cardiol*. 2017;33:1597-1603.
16. Masuda K, Ishizu T, Niwa K, et al. Increased risk of thromboembolic events in adult congenital heart disease patients with atrial tachyarrhythmias. *International journal of cardiology*. 2017;234:69-75.
17. Bouchardy J, Therrien J, Pilote L, et al. Atrial arrhythmias in adults with congenital heart disease. *Circulation*. 2009;120:1679-1686.
18. Waldmann V, Laredo M, Abadir S, Mondesert B, Khairy P. Atrial fibrillation in adults with congenital heart disease. *International journal of cardiology*. 2019.
19. Heidendael JF, Bokma JP, de Groot JR, Koolbergen DR, Mulder BJ, Bouma BJ. Weighing the risks: Thrombotic and bleeding events in adults with atrial arrhythmias and congenital heart disease. *International journal of cardiology*. 2015;186:315-320.

20. Khairy P, Aboulhosn J, Broberg CS, et al. Thromboprophylaxis for atrial arrhythmias in congenital heart disease: A multicenter study. *International journal of cardiology*. 2016;223:729-735.
21. Khairy P, Fernandes SM, Mayer JE, Jr., et al. Long-term survival, modes of death, and predictors of mortality in patients with Fontan surgery. *Circulation*. 2008;117:85-92.
22. Diller GP, Giardini A, Dimopoulos K, et al. Predictors of morbidity and mortality in contemporary Fontan patients: results from a multicenter study including cardiopulmonary exercise testing in 321 patients. *European heart journal*. 2010;31:3073-3083.
23. Pundi KN, Johnson JN, Dearani JA, et al. 40-Year Follow-Up After the Fontan Operation: Long-Term Outcomes of 1,052 Patients. *Journal of the American College of Cardiology*. 2015;66:1700-1710.
24. Giglia TM, Massicotte MP, Tweddell JS, et al. Prevention and treatment of thrombosis in pediatric and congenital heart disease: a scientific statement from the American Heart Association. *Circulation*. 2013;128:2622-2703.
25. McCrindle BW, Manlhiot C, Cochrane A, et al. Factors associated with thrombotic complications after the Fontan procedure: a secondary analysis of a multicenter, randomized trial of primary thromboprophylaxis for 2 years after the Fontan procedure. *Journal of the American College of Cardiology*. 2013;61:346-353.
26. Balling G. Fontan Anticoagulation: A Never-Ending Debate? *Journal of the American College of Cardiology*. 2016;68:1320-1322.
27. Jensen AS, Idorn L, Thomsen C, et al. Prevalence of cerebral and pulmonary thrombosis in patients with cyanotic congenital heart disease. *Heart (British Cardiac Society)*. 2015;101:1540-1546.
28. Silversides CK, Granton JT, Konen E, Hart MA, Webb GD, Therrien J. Pulmonary thrombosis in adults with Eisenmenger syndrome. *Journal of the American College of Cardiology*. 2003;42:1982-1987.
29. Niwa K, Perloff JK, Kaplan S, Child JS, Miner PD. Eisenmenger syndrome in adults: ventricular septal defect, truncus arteriosus, univentricular heart. *Journal of the American College of Cardiology*. 1999;34:223-232.

30. Broberg CS, Ujita M, Prasad S, et al. Pulmonary arterial thrombosis in Eisenmenger syndrome is associated with biventricular dysfunction and decreased pulmonary flow velocity. *Journal of the American College of Cardiology*. 2007;50:634-642.
31. Perloff JK, Hart EM, Greaves SM, Miner PD, Child JS. Proximal pulmonary arterial and intrapulmonary radiologic features of Eisenmenger syndrome and primary pulmonary hypertension. *The American journal of cardiology*. 2003;92:182-187.
32. Daliento L, Somerville J, Presbitero P, et al. Eisenmenger syndrome. Factors relating to deterioration and death. *European heart journal*. 1998;19:1845-1855.
33. Oechslin E, Mebus S, Schulze-Neick I, et al. The Adult Patient with Eisenmenger Syndrome: A Medical Update after Dana Point Part III: Specific Management and Surgical Aspects. *Current cardiology reviews*. 2010;6:363-372.
34. Diller GP, Korten MA, Bauer UM, et al. Current therapy and outcome of Eisenmenger syndrome: data of the German National Register for congenital heart defects. *European heart journal*. 2016;37:1449-1455.
35. Sandoval J, Santos LE, Cordova J, et al. Does anticoagulation in Eisenmenger syndrome impact long-term survival? *Congenit Heart Dis*. 2012;7:268-276.
36. Ammash N, Warnes CA. Cerebrovascular events in adult patients with cyanotic congenital heart disease. *Journal of the American College of Cardiology*. 1996;28:768-772.
37. Jensen AS, Broberg CS, Rydman R, et al. Impaired Right, Left, or Biventricular Function and Resting Oxygen Saturation Are Associated With Mortality in Eisenmenger Syndrome: A Clinical and Cardiovascular Magnetic Resonance Study. *Circ Cardiovasc Imaging*. 2015;8:e003596.
38. Perloff JK. Systemic complications of cyanosis in adults with congenital heart disease. Hematologic derangements, renal function, and urate metabolism. *Cardiol Clin*. 1993;11:689-699.
39. Kuijpers T, Spencer FA, Siemieniuk RAC, et al. Patent foramen ovale closure, antiplatelet therapy or anticoagulation therapy alone for management of cryptogenic stroke? A clinical practice guideline. *Bmj*. 2018;362:k2515.

40. DeSimone CV, Friedman PA, Noheria A, et al. Stroke or transient ischemic attack in patients with transvenous pacemaker or defibrillator and echocardiographically detected patent foramen ovale. *Circulation*. 2013;128:1433-1441.
41. Khairy P, Landzberg MJ, Gatzoulis MA, et al. Transvenous pacing leads and systemic thromboemboli in patients with intracardiac shunts: a multicenter study. *Circulation*. 2006;113:2391-2397.
42. Hoffman M, Monroe DM. Impact of Non-Vitamin K Antagonist Oral Anticoagulants From a Basic Science Perspective. *Arteriosclerosis, thrombosis, and vascular biology*. 2017;37:1812-1818.
43. Mekaj YH, Mekaj AY, Duci SB, Miftari EI. New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events. *Therapeutics and clinical risk management*. 2015;11:967-977.
44. Pollack CV, Jr., Reilly PA, Eikelboom J, et al. Idarucizumab for Dabigatran Reversal. *The New England journal of medicine*. 2015;373:511-520.
45. Jaffer IH, Stafford AR, Fredenburgh JC, Whitlock RP, Chan NC, Weitz JL. Dabigatran is Less Effective Than Warfarin at Attenuating Mechanical Heart Valve-Induced Thrombin Generation. *Journal of the American Heart Association*. 2015;4:e002322.
46. Aimo A, Giugliano RP, De Caterina R. Non-Vitamin K Antagonist Oral Anticoagulants for Mechanical Heart Valves. *Circulation*. 2018;138:1356-1365.
47. Connolly SJ, Milling TJ, Jr., Eikelboom JW, et al. Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors. *The New England journal of medicine*. 2016;375:1131-1141.
48. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. *The New England journal of medicine*. 2011;365:883-891.
49. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. *The New England journal of medicine*. 2013;369:2093-2104.
50. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. *The New England journal of medicine*. 2009;361:1139-1151.
51. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. *The New England journal of medicine*. 2011;365:981-992.

52. De Caterina R, Renda G, Carnicelli AP, et al. Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGE AF-TIMI 48 Trial. *Journal of the American College of Cardiology*. 2017;69:1372-1382.
53. Ezekowitz MD, Nagarakanti R, Noack H, et al. Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: The RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulant Therapy). *Circulation*. 2016;134:589-598.
54. Caldeira D, David C, Costa J, Ferreira JJ, Pinto FJ. Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and valvular heart disease: systematic review and meta-analysis. *European heart journal. Cardiovascular pharmacotherapy*. 2018;4:111-118.
55. Vinereanu D, Wang A, Mulder H, et al. Outcomes in anticoagulated patients with atrial fibrillation and with mitral or aortic valve disease. *Heart (British Cardiac Society)*. 2018;104:1292-1299.
56. Pan KL, Singer DE, Ovbiagele B, Wu YL, Ahmed MA, Lee M. Effects of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta-Analysis. *Journal of the American Heart Association*. 2017;6:e005835.
57. Breithardt G, Baumgartner H, Berkowitz SD, et al. Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial. *European heart journal*. 2014;35:3377-3385.
58. Carnicelli AP, De Caterina R, Halperin JL, et al. Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves. *Circulation*. 2017;135:1273-1275.
59. Steffel J, Verhamme P, Potpara TS, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. *European heart journal*. 2018;39:1330-1393.
60. Windecker S, Tijssen J, Giustino G, et al. Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study. *American heart journal*. 2017;184:81-87.

61. Savarese G, Giugliano RP, Rosano GM, et al. Efficacy and Safety of Novel Oral Anticoagulants in Patients With Atrial Fibrillation and Heart Failure: A Meta-Analysis. *JACC. Heart failure*. 2016;4:870-880.
62. Xiong Q, Lau YC, Senoo K, Lane DA, Hong K, Lip GY. Non-vitamin K antagonist oral anticoagulants (NOACs) in patients with concomitant atrial fibrillation and heart failure: a systemic review and meta-analysis of randomized trials. *Eur J Heart Fail*. 2015;17:1192-1200.
63. Park CS, Choi EK, Kim HM, Lee SR, Cha MJ, Oh S. Increased risk of major bleeding in underweight patients with atrial fibrillation who were prescribed non-vitamin K antagonist oral anticoagulants. *Heart Rhythm*. 2017;14:501-507.
64. Dimopoulos K, Diller GP, Koltsida E, et al. Prevalence, predictors, and prognostic value of renal dysfunction in adults with congenital heart disease. *Circulation*. 2008;117:2320-2328.
65. Diener HC, Aisenberg J, Ansell J, et al. Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2. *European heart journal*. 2017;38:860-868.
66. Siontis KC, Zhang X, Eckard A, et al. Outcomes Associated With Apixaban Use in Patients With End-Stage Kidney Disease and Atrial Fibrillation in the United States. *Circulation*. 2018;138:1519-1529.
67. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. *Journal of the American College of Cardiology*. 2019.
68. Lui GK, Saidi A, Bhatt AB, et al. Diagnosis and Management of Noncardiac Complications in Adults With Congenital Heart Disease: A Scientific Statement From the American Heart Association. *Circulation*. 2017;136:e348-e392.
69. Beyer-Westendorf J, Michalski F, Tittl L, Hauswald-Dorschel S, Marten S. Management and outcomes of vaginal bleeding and heavy menstrual bleeding in women of reproductive age on direct oral anti-factor Xa inhibitor therapy: a case series. *The Lancet. Haematology*. 2016;3:e480-e488.

70. De Crem N, Peerlinck K, Vanassche T, et al. Abnormal uterine bleeding in VTE patients treated with rivaroxaban compared to vitamin K antagonists. *Thrombosis research*. 2015;136:749-753.
71. Chatterjee S, Sardar P, Biondi-Zoccai G, Kumbhani DJ. New oral anticoagulants and the risk of intracranial hemorrhage: traditional and Bayesian meta-analysis and mixed treatment comparison of randomized trials of new oral anticoagulants in atrial fibrillation. *JAMA neurology*. 2013;70:1486-1490.
72. Raparelli V, Proietti M, Cangemi R, Lip GY, Lane DA, Basili S. Adherence to oral anticoagulant therapy in patients with atrial fibrillation. Focus on non-vitamin K antagonist oral anticoagulants. *Thrombosis and haemostasis*. 2017;117:209-218.
73. Chang SH, Chou IJ, Yeh YH, et al. Association Between Use of Non-Vitamin K Oral Anticoagulants With and Without Concurrent Medications and Risk of Major Bleeding in Nonvalvular Atrial Fibrillation. *JAMA*. 2017;318:1250-1259.
74. Denas G, Gennaro N, Ferroni E, et al. Effectiveness and safety of oral anticoagulation with non-vitamin K antagonists compared to well-managed vitamin K antagonists in naive patients with non-valvular atrial fibrillation: Propensity score matched cohort study. *International journal of cardiology*. 2017;249:198-203.
75. Mahaffey KW, Wojdyla D, Hankey GJ, et al. Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial. *Ann Intern Med*. 2013;158:861-868.
76. Diener HC, Aisenberg J, Ansell J, et al. Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1. *European heart journal*. 2017;38:852-859.
77. Renda G, Ricci F, Giugliano RP, De Caterina R. Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Disease. *Journal of the American College of Cardiology*. 2017;69:1363-1371.
78. Avezum A, Lopes RD, Schulte PJ, et al. Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: Findings From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. *Circulation*. 2015;132:624-632.

79. Noseworthy PA, Yao X, Shah ND, Gersh BJ. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and valvular heart disease. *International journal of cardiology*. 2016;209:181-183.

FIGURE LEGEND

Figure: Suggested choices of antithrombotic medications for selected clinical situations in adults with congenital heart disease. Green indicates that NOAC use is reasonable. Yellow indicates that NOACs should be used with caution. Red indicates that VKAs are strongly preferred over NOACs or that NOACs are contraindicated. CHD, congenital heart disease; AV, atrioventricular; VKA, vitamin K antagonist; NOAC, non-vitamin K antagonist oral anticoagulant; > preferred to; AF/IART, atrial fibrillation/intraatrial reentrant tachycardia; TIA, transient ischemic attack.

DISCLOSURES

Dr. François-Pierre Mongeon: no relevant disclosure

Dr. Laurent Macle: Consulting fees/honoraria: BMS/Pfizer, Bayer, Servier; Clinical trials: BMS/Pfizer

Dr. Luc M. Beauchesne: no relevant disclosure

Dr. Berto J. Bouma :no relevant disclosure

Dr. Markus Schwerzmann : no relevant disclosure

Dr. Barbara J.M. Mulder: no relevant disclosure

Dr. Paul Khairy: no relevant disclosure

TABLES

Table 1. Advantages and disadvantages of NOACs relevant to adults with CHD

Advantages	Disadvantages
<ul style="list-style-type: none"> • No dose adjustment required based on frequent monitoring of coagulation parameters • Predictable anticoagulant effect • Fewer food and drug interactions than VKAs • Rapid onset of action • Consistently lower risk of intracranial haemorrhage compared to VKA 	<ul style="list-style-type: none"> • Precautions and contraindications based on renal function • Higher cost than VKAs • Limited experience and availability of reversal agents • Risk of bleeding • Blood levels more difficult to monitor • Paucity of efficacy and safety data specific to adults with CHD • Contraindicated during pregnancy and breastfeeding

VKA denotes vitamin K antagonist; CHD, congenital heart disease

Table 2. Comparison of risk factors and annual rates of stroke or systemic embolism in selected studies

	Adults with CHD	Non-valvular atrial fibrillation									
Study	TACTIC²⁰	RE-LY⁵⁰			ROCKET-AF⁴⁸		ARISTOTLE⁵¹		ENGAGE AF-TIMI 48⁴⁹		
Drugs	Aspirin, VKA or NOAC*	Dabigatran		VKA	Rivaroxaban	VKA	Apixaban	VKA	Edoxaban		VKA
Dose		110 mg bid	150 mg bid		20/15 mg qday		5/2.5 mg bid		60 mg qday	30 mg qday	
N	482	6015	6076	6022	7131	7133	9120	9081	7035	7034	7036
CHADS₂ 0-1 %	93	33	32	31	0	0	34	34	77**	78**	77**
SSE, %/year	1.14	1.53	1.11	1.69	1.7	2.2	1.27	1.60	1.18	1.61	1.50
Major bleeding, %/year	0.77% OAC 0.07% antiplatelet	2.71	3.11	3.36	3.6	3.4	2.13	3.09	2.75	1.61	3.43
Major bleeding in patients aged < 65-75, %/year	Same Mean age 32 years	1.89	2.12 (<75)	3.04 (<75)	2.21	2.16	1.2	1.5	2.02 (<75)	N/A	2.62 (<75)

*37.8% on antiplatelet therapy, *54.4% on oral anticoagulants (OAC, 8.3% on NOACs), 7.9% nothing; **CHADS₂ ≤3; CHD denotes congenital heart disease; VKA, vitamin K antagonist; NOAC, novel oral anticoagulant; SSE, stroke or systemic embolism; bid, twice daily; qday, once daily

Table 3. Summary of outcomes in patients with atrial fibrillation and valvular heart disease treated with a NOAC versus VKA

Study	Study type	N	Type of VHD	NOAC	Treatment favoured in patients with VHD*		
					Stroke and systemic embolism	Major bleeding	Intracranial bleeding
Caldeira D 2018 ⁵⁴	Meta-analysis	12,653	Native VHD Valve repair Bioprosthesis	All	NOAC	NOAC	NOAC
Pan KL 2017 ⁵⁶	Meta-analysis	13,574	Native VHD	All	NOAC	None	NOAC
Renda G 2017 ⁷⁷	Meta-analysis	13,585	Native VHD Valve surgery	All	NOAC	None	NOAC
Vinereanu D 2018 ⁵⁵	Substudy of ARISTOTLE	3,382	MR	Apixaban 5 / 2.5 mg bid	None	NOAC	NOAC
Vinereanu D 2018 ⁵⁵	Substudy of ARISTOTLE	324	AS	Apixaban 5 / 2.5 mg bid	None	None	None
Vinereanu D 2018 ⁵⁵	Substudy of ARISTOTLE	842	AR	Apixaban 5 / 2.5 mg bid	None	None	None
De Caterina R 2017 ⁵²	Substudy of ENGAGE AF-TIMI 48	2,824	2,250 MR 254 MS 369 AR 165 AS 191 bioprosthesis 123 valve repairs 19 valvuloplasty	Edoxaban 60 mg qday	None	None	None
Carnicelli AP 2017 ⁵⁸	Substudy of ENGAGE AF-TIMI 48	191	131 MVR 60 AVR	Edoxaban 60 or 30 mg qday	None	Low-dose NOAC	N/A
Ezekovitz MD 2016 ⁵³	Substudy of RE-LY	3,950	3,101 MR 193 MS 1,179 TR 97 AR 471 AS	Dabigatran 150 mg bid	NOAC	None	NOAC
Ezekovitz MD 2016 ⁵³	Substudy of RE-LY			Dabigatran 110 mg bid	None	NOAC	NOAC

Breithard G 2014 ⁵⁷	Substudy of ROCKET-AF	1,992 for efficacy 1,999 for safety	1,756 MR 486 AR 215 AS 15 congenital VHD 106 valve procedures 11 other	Rivaroxaban 20 / 15 mg qday	None	Warfarin	None
Avezum A 2015 ⁷⁸	Substudy of ARISTOTLE	4,808	3,526 MR 131 MS 887 AR 384 AS 2,124 TR 251 previous valve surgery	Apixaban 5 / 2.5 mg bid	NOAC	None	NOAC
Noseworthy PA 2016 ⁷⁹	Administrative database review	20,158	19,351 AS, AI or MR 654 MS 74 rheumatic MS 55 valve repairs 24 bioprosthesis	Dabigatran Rivaroxaban Apixaban	NOAC for AS, AI or MR None for MS	None NOAC for AS, AI or MR	N/A

*If no treatment is favoured (none), there is no significant difference in effectiveness or safety between the non-vitamin K antagonist oral anticoagulant (NOAC) and warfarin. Patients may have multiple types of valvular heart disease (VHD). Types of VHD included moderate or severe mitral regurgitation (MR), mild mitral stenosis (MS), moderate or severe aortic stenosis (AS) or regurgitation (AR), moderate or severe tricuspid regurgitation (TR) and valve surgery (other than mechanical prosthetic heart valves). AVR denotes bioprosthetic aortic valve replacement; MVR, bioprosthetic mitral valve replacement; bid, twice daily; qday, once daily; N/A: not available

Table 4. Practical tips for using NOACs relevant to adults with CHD

<p>Baseline information to decide on NOAC eligibility</p> <ul style="list-style-type: none"> • Knowledge of congenital cardiac anatomy and pathophysiology • Knowledge of kidney function, age, and weight • Knowledge of co-medications (notably antiarrhythmic and antiepileptic drugs); consult a pharmacist to assess drug interactions • Knowledge of history of bleeding, especially gastrointestinal bleeding • Assess bleeding risk (HAS-BLED score) • Establish that NOAC use is acceptable in light of the underlying CHD; If in doubt, favour VKA • Assess if patient is likely not to fare well on a VKA (e.g., SAME-TT₂R₂ score > 2)
<p>Initiation of treatment</p> <ul style="list-style-type: none"> • Baseline blood tests: haemoglobin, renal and liver function, full coagulation panel • Choose NOAC and correct dose <ul style="list-style-type: none"> ◦ Improved adherence with once daily regimen • If switching from a VKA: <ul style="list-style-type: none"> ◦ If INR <2: start NOAC ◦ If INR 2-2.5: start NOAC the next day ◦ If INR >2.5: repeat INR in 1-3 days • Decide on need for proton pump inhibitor (limited data) • Educate patient about anticoagulation and medication intake <ul style="list-style-type: none"> ◦ Rivaroxaban intake with food ◦ Strict adherence to prescribed regimen ◦ How to deal with missed doses and suspected overdose • Patient should carry information about anticoagulant therapy • Organise and ensure follow-up
<p>Follow-up</p> <ul style="list-style-type: none"> • Initial follow-up at 1 month then every 3-6 months • Involve specialized nurses in adult CHD during patient follow-up • Check for thromboembolic and bleeding events • Assess co-medications • Assess modifiable risk factors: hypertension, aspirin use, NSAID use, alcohol intake • Assess that choice and dosing of NOAC remain optimal • Determine need for blood tests (haemoglobin, renal and liver function, full coagulation panel): <ul style="list-style-type: none"> ◦ Yearly for all ◦ Every 6 months if age >75 years or frail patient ◦ Tailored if decreased renal function: creatinine clearance/10 in months • Assess adherence and use adherence aids as needed • Reinforce education • Bridging generally not recommended if temporary interruption is needed

Adapted from Steffel et al with permission⁵⁹.

NOAC denotes non-vitamin K antagonist oral anticoagulant; CHD, congenital heart disease; VKA, vitamin K antagonist; SAME-TT₂R₂: female sex, age <60 years, medical history, treatment with VKA interacting drugs, tobacco use, non Caucasian race; NSAID, non steroidal anti-inflammatory drug

Table 1. Advantages and disadvantages of NOACs relevant to adults with CHD

Advantages	Disadvantages
<ul style="list-style-type: none"> • No dose adjustment required based on frequent monitoring of coagulation parameters • Predictable anticoagulant effect • Fewer food and drug interactions than VKAs • Rapid onset of action • Consistently lower risk of intracranial haemorrhage compared to VKA 	<ul style="list-style-type: none"> • Precautions and contraindications based on renal function • Higher cost than VKAs • Limited experience and availability of reversal agents • Risk of bleeding • Blood levels more difficult to monitor • Paucity of efficacy and safety data specific to adults with CHD • Contraindicated during pregnancy and breastfeeding

VKA denotes vitamin K antagonist; CHD, congenital heart disease

Table 2. Comparison of risk factors and annual rates of stroke or systemic embolism in selected studies

	Adults with CHD	Non-valvular atrial fibrillation									
Study	TACTIC²⁰	RE-LY⁵⁰			ROCKET-AF⁴⁸		ARISTOTLE⁵¹		ENGAGE AF-TIMI 48⁴⁹		
Drugs	Aspirin, VKA or NOAC*	Dabigatran		VKA	Rivaroxaban	VKA	Apixaban	VKA	Edoxaban		VKA
Dose		110 mg bid	150 mg bid		20/15 mg qday		5/2.5 mg bid		60 mg qday	30 mg qday	
N	482	6015	6076	6022	7131	7133	9120	9081	7035	7034	7036
CHADS₂ 0-1 %	93	33	32	31	0	0	34	34	77**	78**	77**
SSE, %/year	1.14	1.53	1.11	1.69	1.7	2.2	1.27	1.60	1.18	1.61	1.50
Major bleeding, %/year	0.77% OAC 0.07% antiplatelet	2.71	3.11	3.36	3.6	3.4	2.13	3.09	2.75	1.61	3.43
Major bleeding in patients aged < 65-75, %/year	Same Mean age 32 years	1.89	2.12 (<75)	3.04 (<75)	2.21	2.16	1.2	1.5	2.02 (<75)	N/A	2.62 (<75)

*37.8% on antiplatelet therapy, *54.4% on oral anticoagulants (OAC, 8.3% on NOACs), 7.9% nothing; **CHADS₂ ≤3; CHD denotes congenital heart disease; VKA, vitamin K antagonist; NOAC, novel oral anticoagulant; SSE, stroke or systemic embolism; bid, twice daily; qday, once daily

Table 3. Summary of outcomes in patients with atrial fibrillation and valvular heart disease treated with a NOAC versus VKA

Study	Study type	N	Type of VHD	NOAC	Treatment favoured in patients with VHD*		
					Stroke and systemic embolism	Major bleeding	Intracranial bleeding
Caldeira D 2018 ⁵⁴	Meta-analysis	12,653	Native VHD Valve repair Bioprosthesis	All	NOAC	NOAC	NOAC
Pan KL 2017 ⁵⁶	Meta-analysis	13,574	Native VHD	All	NOAC	None	NOAC
Renda G 2017 ⁷⁷	Meta-analysis	13,585	Native VHD Valve surgery	All	NOAC	None	NOAC
Vinereanu D 2018 ⁵⁵	Substudy of ARISTOTLE	3,382	MR	Apixaban 5 / 2.5 mg bid	None	NOAC	NOAC
Vinereanu D 2018 ⁵⁵	Substudy of ARISTOTLE	324	AS	Apixaban 5 / 2.5 mg bid	None	None	None
Vinereanu D 2018 ⁵⁵	Substudy of ARISTOTLE	842	AR	Apixaban 5 / 2.5 mg bid	None	None	None
De Caterina R 2017 ⁵²	Substudy of ENGAGE AF-TIMI 48	2,824	2,250 MR 254 MS 369 AR 165 AS 191 bioprosthesis 123 valve repairs 19 valvuloplasty	Edoxaban 60 mg qday	None	None	None
Carnicelli AP 2017 ⁵⁸	Substudy of ENGAGE AF-TIMI 48	191	131 MVR 60 AVR	Edoxaban 60 or 30 mg qday	None	Low-dose NOAC	N/A
Ezekovitz MD 2016 ⁵³	Substudy of RE-LY	3,950	3,101 MR 193 MS 1,179 TR 97 AR 471 AS	Dabigatran 150 mg bid	NOAC	None	NOAC
Ezekovitz MD 2016 ⁵³	Substudy of RE-LY			Dabigatran 110 mg bid	None	NOAC	NOAC

Breithard G 2014 ⁵⁷	Substudy of ROCKET-AF	1,992 for efficacy 1,999 for safety	1,756 MR 486 AR 215 AS 15 congenital VHD 106 valve procedures 11 other	Rivaroxaban 20 / 15 mg qday	None	Warfarin	None
Avezum A 2015 ⁷⁸	Substudy of ARISTOTLE	4,808	3,526 MR 131 MS 887 AR 384 AS 2,124 TR 251 previous valve surgery	Apixaban 5 / 2.5 mg bid	NOAC	None	NOAC
Noseworthy PA 2016 ⁷⁹	Administrative database review	20,158	19,351 AS, AI or MR 654 MS 74 rheumatic MS 55 valve repairs 24 bioprosthesis	Dabigatran Rivaroxaban Apixaban	NOAC for AS, AI or MR None for MS	None NOAC for AS, AI or MR	N/A

*If no treatment is favoured (none), there is no significant difference in effectiveness or safety between the non-vitamin K antagonist oral anticoagulant (NOAC) and warfarin. Patients may have multiple types of valvular heart disease (VHD). Types of VHD included moderate or severe mitral regurgitation (MR), mild mitral stenosis (MS), moderate or severe aortic stenosis (AS) or regurgitation (AR), moderate or severe tricuspid regurgitation (TR) and valve surgery (other than mechanical prosthetic heart valves). AVR denotes bioprosthetic aortic valve replacement; MVR, bioprosthetic mitral valve replacement; bid, twice daily; qday, once daily; N/A: not available

Table 4. Practical tips for using NOACs relevant to adults with CHD

<p>Baseline information to decide on NOAC eligibility</p> <ul style="list-style-type: none"> • Knowledge of congenital cardiac anatomy and pathophysiology • Knowledge of kidney function, age, and weight • Knowledge of co-medications (notably antiarrhythmic and antiepileptic drugs); consult a pharmacist to assess drug interactions • Knowledge of history of bleeding, especially gastrointestinal bleeding • Assess bleeding risk (HAS-BLED score) • Establish that NOAC use is acceptable in light of the underlying CHD; If in doubt, favour VKA • Assess if patient is likely not to fare well on a VKA (e.g., SAMe-TT₂R₂ score > 2)
<p>Initiation of treatment</p> <ul style="list-style-type: none"> • Baseline blood tests: haemoglobin, renal and liver function, full coagulation panel • Choose NOAC and correct dose <ul style="list-style-type: none"> ◦ Improved adherence with once daily regimen • If switching from a VKA: <ul style="list-style-type: none"> ◦ If INR <2: start NOAC ◦ If INR 2-2.5: start NOAC the next day ◦ If INR >2.5: repeat INR in 1-3 days • Decide on need for proton pump inhibitor (limited data) • Educate patient about anticoagulation and medication intake <ul style="list-style-type: none"> ◦ Rivaroxaban intake with food ◦ Strict adherence to prescribed regimen ◦ How to deal with missed doses and suspected overdose • Patient should carry information about anticoagulant therapy • Organise and ensure follow-up
<p>Follow-up</p> <ul style="list-style-type: none"> • Initial follow-up at 1 month then every 3-6 months • Involve specialized nurses in adult CHD during patient follow-up • Check for thromboembolic and bleeding events • Assess co-medications • Assess modifiable risk factors: hypertension, aspirin use, NSAID use, alcohol intake • Assess that choice and dosing of NOAC remain optimal • Determine need for blood tests (haemoglobin, renal and liver function, full coagulation panel): <ul style="list-style-type: none"> ◦ Yearly for all ◦ Every 6 months if age >75 years or frail patient ◦ Tailored if decreased renal function: creatinine clearance/10 in months • Assess adherence and use adherence aids as needed • Reinforce education • Bridging generally not recommended if temporary interruption is needed

Adapted from Steffel et al with permission ⁵⁹.

NOAC denotes non-vitamin K antagonist oral anticoagulant; CHD, congenital heart disease; VKA, vitamin K antagonist; SAMe-TT₂R₂: female sex, age <60 years, medical history, treatment with VKA interacting drugs, tobacco use, non Caucasian race; NSAID, non steroidal anti-inflammatory drug

*in absence of shunt closure